Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. (22nd June 2015)

• Record Type: Journal Article
• Authors: Cho, Kyoung-Min; Oh, Do-Youn; Kim, Tae-Yong; Lee, Kyung Hun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue
• Is Part Of: Oncologist. Volume 20:Number 8(2015)
• Page Start: 926
• Page End: 933
• Publication Date: 2015-06-22
• Subjects: Advanced biliary tract cancer -- Metabolism -- Prognosis -- Positron emission tomography -- Standardized uptake value; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2014-0356
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Background: In advanced biliary tract cancer (BTC), the metabolic landscape has not been evaluated by 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) yet. Furthermore, reports of the clinical implications of these metabolic features are limited. We aimed to evaluate the metabolic features and their clinical relevance in advanced BTC using 18 F-FDG PET. Patients and Methods: We consecutively enrolled patients with advanced BTC who underwent 18 F-FDG PET prior to palliative chemotherapy between 2003 and 2013. We evaluated the findings of PET, such as SUVmax, the number of lesions and organs with FDG uptake, pathologic findings, and clinical outcomes. Results: A total of 106 patients were enrolled: (53 intrahepatic cholangiocarcinoma [ICC], 7 extrahepatic BTC, 30 gallbladder cancer [GB Ca], and 16 ampulla of Vater cancer [AoV Ca]). The median SUVmax differed according to the primary origin (ICC, 9.10; extrahepatic BTC, 5.90; GB Ca, 9.10; and AoV Ca, 6.37; p = .008) and histologic differentiation (well differentiated, 4.95; moderately differentiated, 6.60; poorly differentiated, 14.50; p = .004). Patients in the high metabolic group (SUVmax of ≥7.5) had more poorly differentiated histology and more organs and lesions with FDG uptake than did those in the low metabolic group (SUVmax of <7.5). The low metabolic group had a significantly longer OS (11.4 vs. 7.4 months, p = .007) and PFS (6.6 vs. 4.3 months, p = .024) than high metabolic group. In multivariate analysis, SUVmax was a significant prognostic factor for overall survival (OS; p = .047) and progression-free survival (PFS; p = .039). Conclusion: Metabolic characteristics of advanced BTC differ according to primary origin and histology. These metabolic features could be prognostic factors for OS and PFS in advanced BTC. Implications for Practice: The metabolic landscape of advanced biliary tract cancer and its clinical meanings have not yet been comprehensively studied. This study shows that metabolic characteristics of advanced biliary tract cancer differ significantly according to primary origin and histology. Moreover, this metabolic activity is associated with patients' outcomes, including overall survival and progression-free survival. This study supports tumor heterogeneity in terms of cancer metabolism in biliary tract cancer. Abstract : This study evaluated 18 F-fluorodeoxyglucose (FDG) positron emission tomography findings in patients with advanced biliary tract cancer (BTC) prior to palliative chemotherapy, such as SUVmax, the number of lesions and organs with FDG uptake, pathologic findings, and clinical outcomes. The metabolic characteristics of advanced BTC differ according to primary origin and histology, which could be prognostic factors for overall survival and progression-free survival in advanced BTC.